Isradipine
CAS: 75695-93-1
Category: Pharmaceutical Intermediates
| Purity | Reagent Grade ≥96%, Standard Grade ≥98%, High-Purity Grade ≥99%, Pharmaceutical Grade ≥98.0–102.0% ( |
| Molecular Formula | C19H21N3O5 |
| Molecular Weight | 371.39 |
| Appearance | Light yellow to yellow crystalline powder or solid |
| Packaging | 5 mg/glass vial, 10 mg/glass vial, 25 mg/glass vial, 50 mg/glass vial, 100 mg/glass vial, 250 mg/glass vial, 1 g/glass vial, 5 g/glass vial, 25 g/HDPE bottle, or 1 kg/aluminum foil bag |
| Testing Indicators | Appearance — Visual inspection (light yellow to yellow crystalline powder or solid); Melting point — Capillary method (166–170°C, FDA Chemistry Review; 166–168°C, ChemicalBook; 156.0–170.0°C, FDA); Boiling point — Distillation (501.9±60.0°C at 760 mmHg, predicted); Density — Hydrometer (1.249±0.06 g/cm³, predicted); Purity — HPLC-UV (≥96–99.5%, C18 column, acetonitrile:buffer gradient, λ=220–254 nm); Related substances — HPLC (impurity profiling including the oxidized pyridine derivative, des-methyl analog, des-isopropyl analog, and other synthesis-related impurities); Assay — RP-HPLC or titrimetric (Thermo Fisher: ≥98.0%; TCI: >98.0% (HPLC); Yeasen: ≥98%; MedChemExpress LCMS: 99.94%); Loss on drying — Gravimetric (≤0.5%); Residue on ignition — Gravimetric (≤0.1%); Heavy metals — Colorimetric/ICP-MS (≤20 ppm); Identification — FTIR (characteristic peaks: N–H (dihydropyridine) ~3300–3400 cm⁻¹, aromatic C–H ~3000–3100 cm⁻¹, aliphatic C–H ~2850–2950 cm⁻¹, ester C=O ~1700–1730 cm⁻¹, aromatic C=C ~1600 cm⁻¹, C–O–C ~1100–1250 cm⁻¹, N–O (benzoxadiazole) ~1300–1400 cm⁻¹); UV spectrophotometry (λmax ~220–260 nm, dihydropyridine chromophore); ¹H NMR (DMSO-d₆ or CDCl₃: δ 1.20 ppm doublet CH₃ (isopropyl), δ 2.30 ppm singlet 2-CH₃, δ 2.40 ppm singlet 6-CH₃, δ 3.60 ppm singlet OCH₃ (methyl ester), δ 4.90 ppm multiplet CH (isopropyl), δ 5.00 ppm singlet 4-H (dihydropyridine), δ 6.80–7.80 ppm multiplet aromatic protons, δ 8.20 ppm broad singlet N–H); ¹³C NMR (DMSO-d₆: δ 18 ppm 2-CH₃, δ 20 ppm 6-CH₃, δ 22 ppm CH₃ (isopropyl), δ 50 ppm OCH₃, δ 68 ppm CH (isopropyl), δ 105 ppm C4 (dihydropyridine), δ 120–150 ppm aromatic carbons, δ 165–170 ppm ester C=O); Mass spectrometry — ESI-MS (m/z 372 [M+H]⁺); Water content — Karl Fischer titration (GB/T 6283/EP 2.5.12); pH — Not applicable (practically insoluble in water); Specific optical rotation — Not applicable (racemic mixture, (4RS)-configuration); Solubility — DMSO (~26 mg/mL), ethanol, methanol, practically insoluble in water. |
| Storage Notes | Store in a cool, dry, well-ventilated area at 2–8°C. Protect from light, moisture, and air. Keep container tightly sealed. Store powder at -20°C for long-term stability (up to 3 years); at 4°C for 2 years. In solvent, store at -80°C for 2 years or at -20°C for 1 year. Light-sensitive and moisture-sensitive material; avoid prolonged exposure to light and humid conditions. TCI recommends storage in a cool and dark place below 15°C. Store away from strong oxidizing agents and incompatible substances. Use inert atmosphere (nitrogen or argon) for long-term storage if available. |
| Lead Time | 10 days |
Isradipine (INN, also known as PN 200-110, Dynacirc, DynaCirc CR, Lomir, or Prescal) is a potent, orally active L-type calcium channel blocker (dihydropyridine class). It functions as a peripheral vasodilator with selective actions on both cardiac and peripheral circulation, inhibiting voltage-gated calcium channels to reduce vascular smooth muscle contraction and lower blood pressure. It exhibits high selectivity for vascular smooth muscle over myocardial tissue. Used as a pharmaceutical intermediate and active pharmaceutical ingredient (API) for the development and quality control of oral capsule and extended-release tablet formulations. Approved for clinical use in the treatment of hypertension and chronic stable angina pectoris. Also investigated as a potentially viable neuroprotective agent for Parkinson's disease due to its selective action on substantia nigra dopaminergic neurons. ATC code: C08CA03.